More Business Wire
View Older Stories View Newer Stories-
Aryaka Announces Partnership with TD SYNNEX
-
Marcus & Millichap, Inc. to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
-
Dynatrace Opens New Corporate Headquarters in Boston
-
WisdomTree Launches Europe Defense Fund (WDEF)
-
Kore.ai Announces the Availability of Its AI for Work, AI for Process, and AI for Service in the New AWS Marketplace AI Agents and Tools Category
-
Overture Life Signs Agreement With Memorial Hospital Istanbul for World’s First Commercial Automated IVF Technology
-
Dualboot Partners Announces Availability of 3PO in the New AWS Marketplace AI Agents and Tools Category
-
Knipper Health, Backed by Frazier Healthcare Partners, Acquires eBlu Solutions to Create Industry-Leading Therapy Initiation Platform
-
Cizzle Brands’ CWENCH Hydration™ Now Sold in Over 300 Sobeys Locations Across Canada
-
Cybersecurity Firm AppSecure Identifies Critical Flaw in Meta.AI Leaking Users’ AI Prompts and Responses, Rewarded $10,000
-
QT Imaging Launches QTviewer 2.8 to Enhance Clinical Efficiency and Diagnostic Accuracy
-
MasTec Schedules Second Quarter 2025 Earnings Conference Call
-
Webster Reports Second Quarter 2025 EPS of $1.52
-
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
-
OFG Bancorp Reports 2Q25 Results
-
Distribution Solutions Group Announces Timing for Second Quarter Results and Conference Call
-
Top-Ranked Coastline Real Estate Group Joins Real
-
Gannett Schedules Second Quarter 2025 Results
-
APi Group Confirms Date of Second Quarter 2025 Earnings Release
-
Ant International Expands Merchant Payment AI Functions With Antom Copilot 2.0
-
Hunan TV: Malaysian Singer Jess Lee Delivered an Amazing Performance on Singer 2025
-
Elucid Names Richard E. Kuntz, MD, MSc and Shamiram Feinglass, MD, MPH Board Directors
-
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
-
Exchange Income Corporation Announces July 2025 Dividend
-
Mobix Labs Secures Surge of High-Value Defense Orders, Igniting Growth in its Filter Interconnect Products
-
US FDA Approves GSK’s SHINGRIX in a Prefilled Syringe Presentation
-
F5 and MinIO Expand Strategic Partnership to Power High-Performance, Secure, and Scalable Data Pipelines for AI Factories
-
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy
-
An Increase in Home Appliance Technology Brings Decrease in Satisfaction, J.D. Power Finds
-
Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM
-
Great Hill Partners Welcomes Seasoned Healthcare Executive Shannon Delage as Growth Partner
-
OneWater Marine Inc. Announces Fiscal Third Quarter 2025 Earnings Release Date and Conference Call Information
-
ACI Worldwide Named to CNBC’s World’s Top Fintech Companies and TIME’s America’s Best Mid-Size Companies 2025 Lists
-
Intel 471 Partners with Sumo Logic to Provide Organizations Exceptional Visibility into the Attack Landscape
-
Paystand Vaults into Elite CNBC/Statista Top Global Fintech List
-
Roblox Continues to Advance Safety Innovations, Launching Age Estimation, Empowering Teens to Connect With People They Know and Trust, and Additional Features
-
Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
-
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
-
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
-
Veritone’s AI-Powered Tools Assessed “Awardable” for Department of Defense Work in the P1 Solutions Marketplace
-
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
-
ActiveCampaign Named a Leader in IDC MarketScape: AI-Enabled Marketing Platforms for Small Businesses
-
Genius Sports to Announce Second Quarter 2025 Results on August 6
-
SelectQuote Unveils New Program Designed to Elevate Health Plan Performance by Improving Medication Adherence for Polychronic Medicare Beneficiaries
-
Kinaxis Inc. to Host Second Quarter 2025 Financial Results Conference Call on August 7, 2025
-
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
-
Travelers Reports Excellent Second Quarter and Year-to-Date Results
-
AECOM selected to design major track improvements for England’s busiest passenger railway corridors
-
Janus International Group to Report Second Quarter 2025 Results on August 7, 2025
-
Leading the AI Revolution in Retail: EDITED Introduces Research AI
